博腾首个商业化产品LCA与PCF通过第三方核查

近期，重庆博腾制药科技股份有限公司（以下简称"博腾"）首个商业化产品的生命周期评估（Life Cycle Assessment, LCA）与产品碳足迹（Product Carbon Footprint, PCF）研究顺利通过第三方机构 SGS 核查。该项研究遵循 ISO 14040:2006 和 ISO 14044:2006（生命周期评估）与 ISO 14067:2018（产品碳足迹）标准，覆盖"从摇篮到大门"（cradle-to-gate）系统边界，标志着博腾的 ESG 管理从组织层面正式延伸至产品层面。

本次 LCA 研究依据 ISO 14040:2006 与 ISO 14044:2006 标准，按照四阶段框架执行——目标与范围界定、生命周期清单分析（Life Cycle Inventory, LCI）、生命周期影响评价（Life Cycle Impact Assessment, LCIA）及结果解释。PCF 核算进一步遵循 ISO 14067:2018 对温室气体量化与报告的专项要求，聚焦气候变化单一影响类别，以每千克产品为功能单位进行核算。

本次研究采用"从摇篮到大门"的系统边界，涵盖上游原材料获取与运输、工艺用能与公用工程消耗、生产制造过程排放、废弃物处理及包装材料等。数据来源以公司运营实测数据为基础，结合行业公认的生命周期清单数据库，确保核算结果的可追溯性与可重复性。第三方核查机构依据 ISO 14064-3 及 ISO 14065 相关要求，对研究的目标与范围界定、数据质量、方法学选择及结果报告进行了独立、系统的核查，并出具核查声明，保证等级为合理保证。

作为客户值得信赖的 CDMO 伙伴，博腾不仅致力于交付高质量的研发与生产服务，也致力于为客户的 ESG 目标提供可验证的数据支撑。LCA 与 PCF 能力的建立，是公司从组织层面温室气体管理向产品层面环境绩效管理延伸的关键举措。通过识别产品全生命周期中的环境热点，公司能够更有针对性地推动工艺优化、创新技术应用及供应链协同减排，实现环境绩效与业务价值的协同提升。

Porton Achieves Third-Party Verification for Its First Commercial Product LCA and PCF Study

Porton Pharma Solutions Ltd. ("Porton") announced that its first commercial product Life Cycle Assessment (LCA) and Product Carbon Footprint (PCF) study has successfully completed independent third-party verification by SGS. Conducted in accordance with ISO 14040:2006 and ISO 14044:2006 (Life Cycle Assessment) and ISO 14067:2018 (Product Carbon Footprint) standards, the study employs a cradle-to-gate system boundary, marking the formal extension of Porton's ESG management from the organizational level to the product level.

The LCA study was conducted in accordance with ISO 14040:2006 and ISO 14044:2006, following the four-phase framework — goal and scope definition, Life Cycle Inventory (LCI) analysis, Life Cycle Impact Assessment (LCIA), and interpretation. The PCF calculation further adheres to the specific requirements of ISO 14067:2018 for greenhouse gas quantification and reporting, focusing on the single impact category of climate change, with a functional unit of one kilogram of product.

The study employs a cradle-to-gate system boundary, covering upstream raw material acquisition and transportation, process energy and utility consumption, manufacturing process emissions and waste treatment, and packaging materials. Data is primarily sourced from the Company's operational measurements, supplemented by industry-recognized life cycle inventory databases, ensuring the traceability and reproducibility of the results. The independent third-party verifier conducted a systematic verification of the study's goal and scope definition, data quality, methodological choices, and result reporting in accordance with ISO 14064-3 and ISO 14065, and has issued a verification statement with a reasonable assurance level.

As a trusted CDMO partner, Porton is committed not only to delivering high-quality R&D and manufacturing services, but also to providing verifiable data to support customers' ESG objectives. The establishment of LCA and PCF capabilities is a key initiative in the Company's evolution from organizational-level greenhouse gas management to product-level environmental performance management. By identifying environmental hotspots across the product life cycle, Porton can drive targeted process optimization, innovative technology adoption, and collaborative value chain decarbonization, delivering shared value for both environmental performance and business growth.

博腾股份成立于2005年，为全球药企、生物科技公司及科研机构等提供从临床前研究到药品上市全生命周期的端到端 CDMO 服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。截至2026年6月30日，公司拥有全球员工4,400余人，累计服务客户1,500余家，成功交付项目约6,000个。我们始终坚持以客户为中心，致力于提供创新可靠的全球化 CDMO 解决方案，让好药更早惠及大众。

(博腾股份 动态宝)